Trending Now
Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) Submits Clinical...
Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have submitted clinical study data for their COVID019 vaccine to the FDA for children 5-11...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
MorphoSys AG (NASDAQ:MOR) and Incyte Corporation (NASDAQ:INCY) Announce EU MAA validation...
MorphoSys AG (NASDAQ:MOR) and Incyte Corporation (NASDAQ:INCY) have announced the European Marketing Authorization Application (MAA) validation for the anti-CD19 antibody tafasitamab.
MorphoSys and Incyte seeking...
MAKE IT MODERN
LATEST REVIEWS
Cytokinetics Incorporated (NASDAQ:CYTK) Commences Phase 1 Clinical Trial of CK-271 In...
Cytokinetics Incorporated (NASDAQ:CYTK) has announced the dosing of the first subjects in Phase 1 single-ascending doses, placebo-controlled CK-3772271 (CK-271) clinical study. CK-271 is the...
MAKE IT MODERN
PERFORMANCE TRAINING
Cyclacel Pharmaceuticals (NASDAQ: CYCC) Sees Significant Stock Volatility Amid New Financing Deal
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC), a prominent biopharmaceutical company focused on the development of innovative cancer therapies, recently witnessed significant stock price...
CohBar Inc. (NASDAQ: CWBR) Reports Q3 2021 Financial Results and Updates on CB4211 Development...
CohBar Inc. (NASDAQ: CWBR) has announced its Q3 20221 financial results for the quarter ending September 30, 2021.
CB4211 demonstrated a promising impact
CEO of CohBar,...
Promising Developments in Waldenstrom Macroglobulinemia Treatment: Mustang Bio’s Latest Clinical Trial Results ($MBIO)
Mustang Bio, Inc. (Nasdaq: MBIO), a trailblazer in clinical-stage biopharmaceuticals, is making significant strides in cell therapy treatments aimed at curing challenging...
CASI Pharmaceutical Inc. (NASDAQ: CASI) announced FDA approval granted Juventas Cell Therapy ODD for...
CASI Pharmaceutical Inc. (NASDAQ: CASI) has announced that US FDA has granted its partner Juventas Cell Therapy Ltd. an Orphan Drug Designation for its...
Clinical Trial of Experimental Ulcerative Colitis Drug Humming Along
Investors generally expect clinical trials to take a long time. That’s not always the case. Take Innovation Pharmaceuticals (OTCQB:IPIX), for example. Looking...
MAKE IT MODERN
